Correlations of breast carcinoma biomarkers and p53 tested by FASAY and immunohistochemistry

Pathology Research and Practice

Volumn 199, Issue 12, 2003, Pages 795-801

  Vagunda, Václav ^a   Šmardová, Jana ^a   Vagundová, Marcela ^a   Jandáková, Eva ^a   Žaloudík, Jan ^a   Koukalová, Hana ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Breast carcinoma; FASAY; Immunohistochemistry; p53; Prognostic predictive factors

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; STEROID RECEPTOR;

ADULT; AGE; AGED; ALLELE; ANALYTIC METHOD; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PREDICTION; PROGNOSIS; RELIABILITY; TUMOR CLASSIFICATION; YEAST;

EID: 1242285543     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1078/0344-0338-00498     Document Type: Article

References (70)

1. Allred DC, Harvey JM, Berardo M, Gary M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168
2. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL (1993) Prognostic significance of TP53 alterations in breast carcinoma. Brit J Cancer 68: 540-548
3. Bankfalvi A, Tory K, Kemper M, Breukelmann D, Cubick C, Poremba C, Fuzesi L, Lelle RJ, Bocker W (2000) Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and Bcl-2 in breast carcinoma. Pathol Res Pract 196: 489-501
4. Barbareschi M (1996) Prognostic value of the immunohistochemical expression of p53 in breast carcinomas. Apll Imunohistochem 4: 106-116
5. Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Palma PD, Harris A (1996) Bcl-2 and p53 expression in node-negative breast carcinoma. Human Pathol 27: 1149-1155
6. Bebenek M, Bar JK, Harlozinska A, Sedlaczek P (1998) Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement. Anticanc Res 18: 619-623
7. Berardo MD, Elledge RM, deMoor C, Clark GM, Osborne CK, Allred DC (1998) Bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer 82: 1296-1302
8. Bergh J, Norberg T, Sjögren S, Lindren A, Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Medicine 1: 1029-1034
9. Berns EMJJ, van Staveren IL, Look MP, Smid M, Klijn JGM, Foekens JA (1998) Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Brit J Cancer 77: 1130-1136
10. Bianchi S, Calzolari A, Vezzosi V, Zampi G, Cardona G, Cataliotti L, Bonardi R, Ciatto S (1997) Lack of prognostic value of p53 protein expression in node-negative breast cancer. Tumori 83: 669-672
11. Blagosklonny MV (1997) Loss of function and p53 protein stabilization. Oncogene 15: 1889-1893
12. Blaszyk H, Hartmann A, Cunningham JM, Schaid D, Wold LE, Kovach JS, Sommer SS (2000) A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome. Int J Cancer 89: 32-38
13. Bonnefoi H, Ducraux A, Movarekhi S, Pelte MF, Bongard S, Lurati E, Iggo R (2002) p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients. Br J Cancer 86: 750-755
14. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L (2000) p53 but not Bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6: 2751-2758
15. Castiglione F, Sarotto I, Fontana V, Destefanis M, Venturino A, Ferro S, Cardaropoli S, Orengo MA, Porcile G (1999) Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients. Anticancer Res 19: 4555-4563
16. Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ (1998) p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 16: 470-479
17. Degeorges A, de Roquancourt A, Extra JM, Espie M, Bourstyn E, de Cremoux P, Sousi T, Marty M (1998) Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer? Breast Cancer Res Treat 47: 47-55
18. Diaz-Cano SJ, Gracia-Moliner M, Carney W, Wolfe HJ (1997) Bcl-2 expression and DNA fragmentation in breast carcinoma, pathologic and steroid hormone receptors correlates. Diag Mol Pathol 6: 199-208
19. Dublin EA, Miles DW, Rubens RD, Smith P, Barnes DM (1997) p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer. Int J Cancer 19: 605-608
20. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK (1997) Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol 15: 1916-1922
21. Falette N, Paperin MP, Treilleux I, Gratadour AC, Peloux N, Mignotte H, Tooke N, Löfman E, Inganäs M, Bremond A, Ozturk M, Puisieux A (1998) Prognostic value of p53 gene mutations in a large series of node-negative breast cancer patients. Canc Res 58: 1451-1455
22. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher JM, Bron L, Benhattar J, Tada M, Van Meir EG, Estreicher A, Iggo RD (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92: 3963-3967
23. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22: 207-219
24. Gasparini G, Toi M, Verderio P, Ranieri G, Dante S, Bonoldi E, Borrachi P, Fanelli M, Tominaga T (1998) Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients. Int J Oncol 12: 1117-1125
25. Gursan N, Karakok M, Sari I, Gursan MS (2001) The relationship between expression of p53/Bcl-2 and histopathological criteria in breast invasive ductal carcinomas. Int J Clin Pract 55: 589-590
26. Haerslev T, Jacobsen GK (1995) An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen and prognosis. Human Pathology 26: 295-301
27. Hansen R, Oren M. (1997) p53; from inductive signal to cellular effect. Curr Opin Gent Devel 7: 46-51
28. Harn HJ, Shen KL, Yueh KC, Ho LI, Yu JC, Chiu SC, Lee WH (1997) Apoptosis occurs more frequently in intraductal carcinoma than in infiltrating duct carcinoma of human breast cancer and correlates with altered p53 expression: detected by terminal-deoxynucleotidyl-transferase-mediated dUTP-FITC nick end labelling (TUNEL). Histopath 31: 534-539
29. Hurlimann J, Larrinaga B, Vala DL (1995) Bcl-2 protein in invasive ductal breast carcinomas. Virch Arch 426: 163-168
30. Charpin C, DeVictor B, Andrac L, Amabile J, Bergeret D, LaVaut MN, Allasia C, Piana L (1995) p53 quantitative immunocytochemical analysis in breast carcinomas. Human Pathol 26: 159-166
31. Chu JS, Lee WJ, Chang KJ, Hsu HC (1997) Immunohistochemical analyses of p53 protein expression in breast cancers in Taiwan: a clinicopathologic study. J Formos Med Assoc 96: 237-241
32. Iacopetta B, Grieu F, Powell B, Soong R, McCaul K, Seshadri R (1998) Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res 4: 1597-1602
33. Iwaya K, Tsuda H, Fukutomi T, Tsugane S, Suzuki M, Hirohashi S (1997) Histologic grade and p53 immunoreaction as indicators of early recurrence of node-negative breast cancer. Jpn J Clin Oncol 27: 6-12
34. Jansson T, Inganäs M, Sjögren S, Norberg T, Lindgren A, Holmberg L, Berg J (1995) p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol 13: 2745-2751
35. Kato T, Kameoka S, Kimura T, Tanaka S, Nishikawa T, Kobayashi M (2002) p53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer. Anticancer Res 22: 1105-1112
36. Kristen P, Müller JG, Caffier H (1997) Prognostic relevance of p53 in node negative breast cancer. Anticancer Res 17: 2869-2872
37. Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K (1995) Apoptosis suppressing protein Bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 177: 49-55
38. Logullo AF, de Moura RP, Nonogaki S, Kowalski LP, Nagai MA, Simpson AJ (2000) A proposal for the integration of immunohistochemical staining and DNA-based techniques for the determination of TP53 mutations in human carcinomas. Diagn Mol Pathol 9: 35-40
39. Mandavilli SR, Cartun RW, Ricci A, Tsongalis GJ (1997) Immunohistochemical evaluation of genetic and epigenetic factors in primary breast cancers. J Histotech 20: 27-30
40. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, Peterse J (1996) A clinicopathological study on accumulation of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73: 728-734
41. Molina R, Segui MA, Climent MA, Bellmunt J, Albanell J, Fernandez M, Filella X, Jo J, Gimenez N, Iglesias E, Miralles M, Alonso C, Piero G, Perez-Picanol E, Ballesta AM (1998) p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Res 18: 507-511
42. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius VM (1997) Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 76: 917-922
43. O'Malley FP, Saad Z, Kerkvliet N, Doig G, Stitt L, Ainsworth P, Hundal H, Chambers AF, Turnbull DI, Bramwell V (1996) The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer. Human Pathology 27: 955-963
44. Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR (2000) Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 6: 443-451
45. Rozan S, Vincent-Salomon A, Zafrani B, Validire P, De Cremoux P, Bernoux A, Nieruchalski M, Fourquet A, Clough K, Dieras V, Pouillart P, Sastre-Garau X (1998) No significant predictive value of c-erbB-2 or p53 expression regarding sensitivy to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79: 27-33
46. Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia-Ramirez M, Fabra A (1995) Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 60: 54-60
47. Silvestrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, Salvadori B, Veronesi U (1996) Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 2: 2007-2013
48. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U (1994) The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Nat Cancer Inst 86: 499-504
49. Sirvent JJ, Salvado MT, Santafe M, Martinez S, Brunet J, Alvaro T, Palacios J (1995) p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases. Histol Histopathol 10: 531-539
50. Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J (1996) The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88: 173-182
51. Sjöström J, Blomqvist C, Heikkilävon P, von Boguslawski K, Räisänen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmström P, Ostenstadt B, Bergh J, Wist E, Valvere V, Saksela E (2000) Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 6: 3103-3110
52. Smardova J, Nemajerova A, Trbusek M, Vagunda V, Kovarik J (2001) Rare somatic p53 mutation identified in breast cancer: a case report. Tumour Biol 22 (2): 59-66
53. Smardova J, Vagunda V, Jandakova E, Vagundova M, Vojtesek B Koukalova H, Kovarik J, Zaloudik J (1999) p53 status in breast carcinomas revealed by FASAY correlates well with p53 protein accumulation determined by immunohistochemistry. Neoplasma 46: 384-389
54. Soong R, Iacopeta BJ, Harvey JM, Sterrett GF, Dawkins HJS, Hahnel R, Robbins PD (1997) Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer 74: 642-647
55. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S. Williams KE, Turbett GR, House AK, Iacopetta BJ (1996) Corcordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 127: 1050-1055
56. Sundblad AS, Ahn C, Battifora H (1996) Estudio immunohistoquimico de Bcl-2 y MIB-1/KI-67 en el carcinoma de mama. Medicina 56: 252-258
57. Takahashi M, Tonoki H, Tada M, Kashiwazaki H, Furuuchi K, Hamada J, Fujioka Y, Sato Y, Takahashi H, Todo S, Sakuragi N, Moriuchi T (2000) Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 89: 92-99
58. Têtu B, Brisson J, Plante V, Bernard P (1998) p53 and cerbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer. Mod Pathol 11: 823-830
59. van Slooten HJ, van De Vijver MJ, Borresen AL, Eyfjord JE, Valgardsdottir R, Scherneck S, Nesland JM, Devilee P, Cornelisse CJ, van Dierendonck JH (1999) Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma. J Pathol 189: 504-513
60. van Slooten HJ, van de Vijver MJ, van de Velde CJ, van Dierendonck JH (1998) Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer 77: 789-796
61. Visscher DW, Sarkar F, Tabaczka P, Crissman J (1996) Clinicopathologic analysis of Bcl-2 immunostaining in breast carcinoma. Modern Pathol 9: 642-646
62. Visscher DW, Sarkar FH, Shimoyama RK, Crissman JD (1996) Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diag Mol Pathol 5: 187-193
63. Vojtesek B, Bartek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151: 237-244
64. Vojtesek B, Dolezalova H, Lauerova L, Svitakova M, Havlis P, Kovarik J, Midgley CA, Lane DP (1995) Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene 10: 389-393
65. Wynford T (1992) p53 in tumour pathology: can we trust immunohistochemistry? J Pathol 166: 329-330
66. Zaloudik J, Vagunda V, Drahokoupilova M, Janakova L, Talac R, Kalabis J, Sheard M (1997) Biomarkers for predicting response to regional chemo-immunotherapy in liver metastases from colorectal carcinoma. Int J Immunopharmacol 19: 481-485
67. Zellars RC, Hilsenbeck SG, Clark GM, Allred DC, Herman TS, Chamness GC, Elledge RM (2000) Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 18: 1906-1913
68. Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, Tsuichiya A (1998) Apoptotic index correlates to Bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res 18: 1989-1998
69. Zhang GJ, Kimijima I, Tsuchiya A, Abe R (1998) The role of Bcl-2 expression in breast carcinomas (Review). Oncol Reports 5: 1211-1216
70. Zheng WQ, Zhan RZ (1998) Quantitative comparison of apoptosis to cell proliferation and p53 protein in breast carcinomas. Anal Quant Cytol Histol 20: 1-6